Unjha Formulations share price
You have to be logged in to add this to Watchlist.- ₹23.03(-3.76%)May 13, 2025 15:27:36 PM IST
- NSE
- BSE
- Vol : 0.60K (NSE + BSE)Last 20 day avg : 1.88 K
Unjha Formulations is trading -3.76% lower at Rs 23.03 as compared to its last closing price. Unjha Formulations has been trading in the price range of 25.35 & 22.65. Unjha Formulations has given -21.21% in this year & 1.79% in the last 5 days. Unjha Formulations has TTM P/E ratio 21.40 as compared to the sector P/E of 45.69.The company posted a net profit of 0.22 Crores in its last quarter.Listed peers of Unjha Formulations include Vanta Bioscience (4.98%), Decipher Labs (5.05%), Unjha Formulations (-3.76%).The Mutual Fund holding in Unjha Formulations was at -% in . The MF holding has - from the last quarter. The FII holding in Unjha Formulations was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 13, 2025, 07:03 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/B3.93The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values16.86Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility-0.45Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 32.15% from Rs 5.55 crore to Rs 3.76 crore, year-on-year- The company's profit declined by 42.33% year-on-year during the December quarter, dropping from Rs 0.39 crore to Rs 0.22 crore
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 24.65
- R2
- 26.58
- R3
- 27.65
- S1
- 21.65
- S2
- 20.58
- S3
- 18.65
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Vanta Bioscience | Bearish | 20.03 | 4.98 | 12.64 | - | 0.79 | - | 321.09 |
| Decipher Labs | Neutral | 11.85 | 5.05 | 11.95 | - | 0.5 | - | - |
| Unjha Formulations | Bearish | 23.03 | -3.76 | 10.32 | 38.68 | 3.94 | - | - |
| Tiaan Consumer | Bullish | 8.43 | - | 18.87 | - | 1.31 | - | - |
| Beryl Drugs | Bearish | 19.10 | 4.09 | 9.69 | 11.66 | 0.99 | - | 26.94 |
- Promoter(s) holding is moderate at 36.92%
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-16 | Audited Results |
| 2025-03-17 | Others |
| 2025-02-04 | Quarterly Results |
| 2024-11-08 | Quarterly Results |
| 2024-08-01 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE576D01015
- BSE Code531762
- NSE Code
Unjha Formulations is trading at 23.03 as on Tue May 13 2025 09:57:36. This is -3.76% lower as compared to its previous closing price of 23.93.
The market capitalization of Unjha Formulations is 10.32 Cr as on Tue May 13 2025 09:57:36.
The 52 wk high for Unjha Formulations is 39.00 whereas the 52 wk low is 19.99
Unjha Formulations can be analyzed on the following key metrics -
- TTM P/E: 21.40
- Sector P/E: 45.69
- Dividend Yield: 0.00%
- D/E ratio: -
Unjha Formulations reported a net profit of 0.28 Cr in 2024.